EncapX® presented at the AFSSI webinar
26 October 2026
As a member of AFSSI, Biotech One was invited to present EncapX® on 27 October at 3:00 pm, Paris time.
The session introduced the liposome and LNP formulation platform, which uses supercritical CO₂ for mRNA or active drugs, with the aim of improving the stability of vaccines, cancer therapies and gene therapies.
The ambition set out for the webinar was to protect fragile molecules, to improve formulation stability, and to bridge R&D and industrial production.
Related news
Biotech One pitches EncapX® to France BioLead members
An exclusive member session on 6 November, on bridging R&D formulation and industrial bioproduction for liposome and LNP manufacturing.
5 November 2026
EncapX® on stage at World Vaccine Congress Europe 2026
Exhibitor in the Start-up Zone (booth SU3). Talk by Dr Elissandro Klein on continuous scCO₂ processing for vaccine delivery.
21 October 2026 · RAI Amsterdam
Poster at the Festival of Biologics, Basel
Elissandro Klein presents a poster on the continuous production of lipid-based nanoparticles using supercritical CO₂ (EncapX®).
9 October 2026 · Basel